Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study
about
Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker.Pathogenic role of endogenous TNF-α in the development of Sjögren's-like sialadenitis and secretory dysfunction in non-obese diabetic mice.Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes.Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.Systematic review and meta-analysis of the efficacy and safety of Biqi capsule in rheumatoid arthritis patients.Sex-based differences in association between circulating T cell subsets and disease activity in untreated early rheumatoid arthritis patients
P2860
Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Baseline CXCL10 and CXCL13 lev ...... is: a pilot, prospective study
@en
type
label
Baseline CXCL10 and CXCL13 lev ...... is: a pilot, prospective study
@en
prefLabel
Baseline CXCL10 and CXCL13 lev ...... is: a pilot, prospective study
@en
P2093
P2860
P1476
Baseline CXCL10 and CXCL13 lev ...... is: a pilot, prospective study
@en
P2093
Bobby Kwanghoon Han
Igor Kuzin
John P Gaughan
Nancy J Olsen
P2860
P2888
P356
10.1186/S13075-016-0995-0
P577
2016-04-22T00:00:00Z
P6179
1040069824